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To gain more insight into the factors controlling efficient
cysteine arylation by cyclometallated AuIII complexes, the
reaction between selected gold compounds and different
peptides was investigated by high-resolution liquid chromatog-
raphy electrospray ionization mass spectrometry (HR-LC-ESI-
MS). The deduced mechanisms of C  S cross-coupling, also
supported by density functional theory (DFT) and quantum
mechanics/molecular mechanics (QM/MM) calculations, evi-
denced the key role of secondary peptidic gold binding sites in
favouring the process of reductive elimination.
The use of metal-based catalysts within living systems is a
research area that has gained significant attention for biological
sensing, imaging, caging applications and therapy.[1] Among the
possible reactions templated by metal compounds in biological
environments, Suzuki-Miyaura,[2] Mizoroki-Heck and
Sonogashira[3] cross-coupling reactions have been described for
PdII compounds and successfully applied to modify biomole-
cules, proteins in particular, and to study their function.[1c]
Recently, some examples have appeared concerning the use of
gold compounds for selective bioorthogonal transformations
through C  C or C  X (X=heteroatom) bond formation for
different applications in chemical biology.[1e] Many of the
investigations exploit the propensity of both AuIII and AuI ions
to activate alkynes towards nucleophilic addition for catalysis.
In this context, selective cysteine arylation using organogold
reagents represents another important example of metal-
mediated bioconjugation reactions. Wong and co-workers[4]
pioneered this approach forming C  S bonds on cysteine
models using the cyclometallated AuIII C^N complex A,
featuring a N,N’-bis(methanesulfonyl)ethylene (msen) ligand
(Figure 1) and derivatives. According to the authors, a com-
pound’s affinity for cysteine arylation was mainly determined
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Figure 1. Structure of organometallic AuIII complexes A and B as well as of
compounds 1–4 studied for their Cys arylation properties.
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by the presence of specific ancillary ligands coordinating AuIII
(e.g., msen vs chlorido) while maintaining the same C^N
scaffold.
In 2018, the oxidative addition complex [(Me–DalPhos)Au
(tolyl)Cl][SbF6] (B, Me–DalPhos=adamantyl2P(o-C6H4)NMe2, Fig-
ure 1) was shown to arylate glutathione in aqueous
environment.[5] Derivatives of B were able to perform C  S cross-
coupling reactions with complex peptide substrates, as
observed by mass spectrometry.[5] However, cysteine arylation
was monitored mostly at short incubation times (1 min) after
addition of the AuIII complexes,[5] which may prevent detection
of other adducts and arylation products likely to occur in a
complex biological environment. Further exploring the poten-
tial of C^N-cyclometallated AuIII complexes for cysteine aryla-
tion in zinc finger (ZF) protein domains of the type Cys2His2,
[6]
we demonstrated the key role of the C^N ligand in modulating
the affinity of the complexes towards C  S coupling through
reductive elimination.[7] Among the selected AuIII compounds,
featuring different C^N scaffolds, the [Au(CCON)Cl2] complex (1,
CCON=2-benzoylpyridine, Figure 1) was identified as the most
prone to cysteine arylation in buffered aqueous solution
(pH 7.4) at 37 °C by mass spectrometry.[7] Density functional
theory (DFT) and quantum mechanics/molecular mechanics
(QM/MM) studies supported a mechanism which includes the
following steps: i) substitution of one of the two chlorido
ligands with cysteinate from the peptide, ii) apical approach of
a second cysteinate residue inducing the displacement of the N
atom of the C^N ligand from gold, and iii) reductive elimination
leading to the C  S cross-coupling product and to the AuI side
complex.[7] The obtained results corroborated the idea that the
specificity and efficiency in gold-ligand binding and subsequent
C  S transfer may be modulated both by the nature of the gold
compound, as well as by the nucleophilicity and accessibility of
the cysteines in the folded peptide, leading to stabilization of
the various reaction intermediates. Notably, reductive elimina-
tion with “free” cysteine residues was never observed in
aqueous solution.
Using a hyphenated mass spectrometry approach, we
further explore the reactivity and chemoselectivity of cyclo-
metallated AuIII complexes towards different model peptides,
namely the Cys2His2 zinc finger domain (ZF), four different
peptides, with and without cysteine residues available for
arylation, and towards glutathione (GSH; Figure 1). The model
peptides with sequences ANGELACASINI (AC), CASINI (C) and
LFRANALK (L) were synthesized and characterized as described
in the experimental section (Figures S1–S6 in the Supporting
Information). The small library of AuIII compounds include
cyclometallated AuIII complexes with bidentate C^N ligands-1,[8]
2 [Au(CSN)Cl2] (CSN=2-(phenylthiol)pyridine)[9] and 3 [Au(CON)
Cl2] (C
ON=2-phenoxypyridine)[9] as well as with a tridentate
C^N^N ligand-4 [Au(bipydmb-H)Cl][PF6] (bipydmb=6-(1,1-dimeth-
ylbenzyl)-2,2’-bipyridine;[10] Figure 1). The latter AuIII C^N^N
scaffold has never been explored before for cysteine arylation.
Initially, each gold complex was incubated separately with the
peptides in (NH4)2CO3 buffer (25 mM, pH 7.4) and the samples
analysed at different incubation times (30 min and 24 h at
37 °C) by high-resolution liquid chromatography electrospray
ionization mass spectrometry (HR-LC-ESI-MS) following previ-
ously reported procedures[7,11] (see also the Experimental
Section for details, Figure S7–S25 and Tables S1–S6). Figures 2A
and S7–S10 report representative HR-LC-ESI-MS spectra ob-
tained for complexes 1–4 after 30 min incubation with the ZF
domain. Overall, the four compounds give classical [Apo-ZF+
AuIIIC^N-2H]n + adducts following chlorido ligand substitution
and Zn2+ ejection, as previously observed for similar cyclo-
metallated complexes;[11] however, only the C^N compounds 1–
3 produce the reductive elimination product in which the
peptide is arylated at specific sites. In the case of ZF, up to two
arylation sites can be detected to give [Apo-ZF+2 C^N-2H]n +
adducts, most likely corresponding to the two cysteine residues
in the ZF domain (Table S1). Compound 3 also provides [Apo-
ZF+AuIIICON+CON+3H]6+ adducts. Instead, complex 4 affords
only bis-adducts in which the AuIII centre maintains the C^N^N
ligand [Apo-ZF+2AuIIIC^N^N-4H]n +, even after 24 h incubation.
Based on the chromatographic analysis, adduct formation is
never quantitative in all cases with respect to the free ZF
peptide even after 24 h (as peaks corresponding to other by-
products were observed); nevertheless, complex 1 is the most
reactive with the ratio of peak area of adduct to free ZF being
largest (Figure S7).
The ANGELACASINI (AC) peptide is very reactive with the
gold complexes, particularly with compound 1 (Figure 2B and
C). After 30 min incubation, the mass spectra of 1–3 show
formation of mono-gold [AC+AuIIIC^N-2H]n + and bis-gold [AC
+2AuIIIC^N-4H]n + adducts, reductive elimination [AC+
C^N  H]n + products, as well as their co-existence [AC+AuIIIC^N
+C^N-3H]n + on the same peptide molecule (Figures 2 and
S11–S13, Table S2). In stark contrast, peptide arylation occurs
only at one site, at variance with the case of the ZF peptide,
and yet the peptide is able to offer a second Au binding site
other than cysteine. After 24 h, the high reactivity of compound
1 favours complete peptide decomposition (data not shown),
whereas complexes 2 and 3 still form intact [AC+AuIIIC^N+
C^N  H]2+ adducts (Figure S12, Table S2). The cleavage of AC by
1 may occur by hydrolysis of the backbone amide bonds, as
already reported for PtII and PdII complexes.[12] Compound 4
does not produce arylation products, but only mono-adducts of
the type [AC+AuIIIC^N^N]2+ (Figure S13, Table S2). Inspection
of the chromatograms shows that adduct formation is almost
quantitative after 30 minutes’ incubation in all cases (data not
shown).
Carrying a N-terminal cysteine residue, the CASINI (C)
peptide reacts with all compounds after 30 min forming mainly
mono-gold adducts of the type [C+AuIIIC^N  H]+ (1–3; Figur-
es S14–S16, Table S3) and [C+AuIIIC^N^N  H]+ (4; Figure S17).
This result is interesting as it suggests that, despite the
presence of the cysteine as in peptide AC, the fact that this
residue now occupies the N-terminal position does not favour
reductive elimination. In any case, compound 3 also produces
[C+2AuIIICON-3H]+ adducts, as detected after 30 min incuba-
tion, thus, indicating the presence of a secondary gold binding
site, as in the case of the AC peptide (Figure S16, Table S3).
After 24 h, the spectra show substantially the same types of
adducts (Table S3).
ChemBioChem
Communications
doi.org/10.1002/cbic.202000262
3072ChemBioChem 2020, 21, 3071–3076 www.chembiochem.org © 2020 The Authors. Published by Wiley-VCH Verlag GmbH & Co. KGaA
Wiley VCH Donnerstag, 22.10.2020
2021 / 171200 [S. 3072/3076] 1
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
The gold complexes were also reacted with GSH, and
whereas 1–3 were able to fully arylate the peptide forming
[GSH+C^N]+ adducts (Figure S18), complex 4 could only form
AuIII adducts of the type [GSH+AuIIIC^N^N  H]+ even after
24 hours’ incubation (Figure S19, Table S6). In this latter case,
no reduction of the AuIII centre could be observed despite the
reducing power of GSH, in line with previous studies of 4 with
other physiologically relevant reducing agents.[13] In order to
evaluate the chemoselectivity of the arylation product by the
AuIII complexes, peptide LFRANALK (L) was reacted with the
compounds under the same conditions.
At both 30 min and 24 h, compounds 1–3 give mainly
mono-gold [L+AuIIIC^N]2+ adducts (Figure S20–S22, Table S4),
and only 3 produces adducts where the gold centre has been
reduced to the type [L+AuI+H]2+. In any case, no reductive
elimination product is detected in all cases. Finally, compound
4 is completely unreactive even after 24 h incubation, further
demonstrating its binding preference for cysteine containing
peptides.[14] To confirm our observations, we also reacted the
gold complexes with another cysteine-free peptide model,
namely [Leu5]-enkephalin (YGGFL, LE). The obtained results
showed that the main adduct is the mono-gold [LE+
AuIIIC^N  H]+ species obtained for compounds 1–3 (Table S5,
Figures S23–S25). Similarly, complex 4 was not reactive even
after 24 hours’ incubation. An overview of the types of adduct
formed by complex 1 with the various peptides is included in
Table 1. As LE does not offer classical nucleophilic coordination
partners for the gold complexes, we aimed to identify the
potential binding sites of compound 1 with the LE by using an
online top-down approach. Fragmentation experiments by
collision-induced dissociation (CID) were carried out on the [LE
+AuIIICONH]+ adduct (m/z 933). This fragmentation technique
generates b and y fragment ions.[15] Fragment mass spectra
were analysed using the online software Apm2s recently
reported by Dyson et al.,[16] which allows detection of internal
fragments in addition to N- and C-terminal fragments. The
adduct between the pentapeptide and AuIIICON fragmented
efficiently and complete sequence coverage was achieved
(Figure S26, Table S7). The fragments correspond mainly to b-
fragments, while y-fragments were not detected. Moreover, the
associated a-fragments were detected as well, which are formed
by higher collision energies upon loss of CO from the b-
fragments. Overall, the results suggest two possible binding
modes: the first possibility being N-terminal coordination to the
Phe1, due to fact that metallated a/b-fragments were abundant.
Furthermore, the two internal fragments, corresponding to
a4y3 and a3y3, imply that AuIIIC^N might also be coordinated
to the Gly3Phe4 fragment, most likely via the amide backbone.
A competition experiment was designed to evaluate the
selectivity of compound 1 for the ZF in presence of peptide LE.
Thus, 1 (3 equiv.) was reacted with the two different model
peptides (1 equiv. each) for 30 min and studied by HR-LC-ESI-
Figure 2. HPLC-ESI-MS analysis of the reaction of the AuIII CCON complex 1 with A) ZF or B) AC peptides ((NH4)2CO3 buffer 25 mM, pH 7.4) after 30 min
incubation at 37 °C. Representative mass spectra recorded at retention times (tR) of 3.96 and 5.32 min, respectively. Comparisons between experimental and
theoretical isotopic pattern distributions for selected adducts corresponding to Cys-arylated products. C) Model of the ANGELACASINI (AC) peptide. Drawing
produced by using the UCSF Chimera package.
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MS.[11] The results show that no gold adducts were observed
with LE after 30 min incubation, whereas AuIII-ZF adducts were
identified similarly to the individual experiments, that is [Apo-
ZF+AuIIICCON-2H]n + (Figure S27, peak at tR=3.81 min).
An atomistic support of the experimental results was
achieved by DFT calculations, which evaluated the binding
energy of compound 1 upon forming monodentate adducts (by
exchange of one chlorido ligand) with amino acids that possibly
act as AuIII binding sites (see the Experimental Section for
details, Figures S28–S29, Table S8). As expected based on the
hard–soft acid–base (HSAB) theory, the most stable adduct is
formed with the thiol of cysteine residues ([Au(CCON)ClCys],
ΔG°=   90.9 kJ/mol), followed by the N-containing side chains
of arginine ([Au(CCON)ClArg]+, ΔG°=   44.5 kJ/mol) asparagine
([Au(CCON)ClAsn], ΔG°=   42.0 kJ/mol) and glutamine (([Au
(CCON)ClGln], ΔG°=   37.5 kJ/mol). Interestingly, the compound
also has weak affinity for binding to O donors in tyrosine and
serine residues ([Au(CCON)ClTyr/Ser] ΔG°=   38.3 and   35.5 kJ/
mol, respectively). This data confirm the possibility for 1 to
coordinate different nucleophiles.
Following the mechanistic hypothesis of cysteine arylation
via reductive elimination in Cys2His2-type zinc finger peptides
formulated in our previous study,[7] we performed DFT calcu-
lations to characterize the stability of the adduct of compound
1 with the AC peptide and to predict the reaction intermediate
leading to the experimentally observed arylation product. As
we observed that the cysteine residue needs to be located
within an amino acid sequence to undergo reductive elimina-
tion, we hypothesize that it is crucial for the AuIII complex to
bind in a bidentate fashion to the peptide, not necessarily
involving a second cysteine residue, for the reaction to proceed
by reductive elimination. Such selectivity is different from many
of the popularly used reagents that typically target N-terminal
cysteine residue.[17]
Modelling the 1-AC adduct, two possible residues accessible
as secondary AuIII binding sites were identified, namely the NH2
groups of the side-chain of Asn2 and Asn11, located on both
sides of the primary binding site Cys7. First, the substitution of
the two chlorido ligands of 1 occurs by the binding of both
Cys7 and Asn11 side-chain residues, forming the reactant R in
our proposed reaction pathway (Figure 3A and B). Then, the
Asn2 substitution of the pyridyl ring of the C^N ligand may
occur providing the intermediate I, which is 114 kJ/mol more
stable than the reactant. Finally, two possible cross-coupling
reactions may take place, both thermodynamically favoured
compared to the intermediate, and involving either i) the Asn2
nitrogen (product P1) or ii) the Cys7 sulfur (product P2;
Figure 3A, B). Side products of P1 and P2 are the AuI complexes
linearly coordinated to the side chains of Asn2 and Asn11 or to
Asn2 and Cys7, respectively. Interestingly, the N-arylation
product is about 20 kJ/mol more stable than the S-arylation
product (–195 vs. –175 kJ/mol, respectively). This result might
be due to the increased stability of the corresponding S-bound
AuI side product included in the calculations, but never
observed experimentally.
Although our MS data does not allow discrimination
between the two possible arylation positions, the identification
of the [AC+AuIIIC^N+C^N  H]2+ species for the bidentate
cyclometallated complexes 2 and 3 suggests the presence of
more than one binding site for AuIII ions relevant to the
mechanism of reductive elimination other than Cys7, possibly
the Asn residues themselves. In fact, a secondary gold binding
site was also identified in the case of the C peptide. Moreover,
the experimental observation that a cysteine in terminal
position does not undergo reductive elimination (as for C) may
be due to the fact that the AuIII centre does not find the ideal
coordination environment to stabilize the intermediate I,
leading to reductive elimination. Instead, the latter can occur
even in short peptidic sequences provided that I can be formed,
Table 1. Overview of the adducts formed by compound 1 with the selected peptides and respective average masses calculated experimentally (Mrexp ) and
theoretically (Mrtheor). At 24 h, decomposition of the AC peptide was recorded.
Peptide tR Adduct Mrexp Mrtheor Δ
[min] [Da] [Da] [Da]
30min
ZF 3.96 [Apo-ZF+ CON] 3143.51 3143.55 0.04
[Apo-ZF+AuCCON] 3339.46 3339.51 0.05
4.25 [Apo-ZF+2CCON] 3325.31 3325.60 0.29
AC 5.15 [AC+AuCCON] 1550.62 1550.61 0.01
[AC+AuCCONCl] 1588.57 1588.60 0.03
5.32 [AC+CCON  H] 1354.65 1354.65 0.0
C 5.2 [C+AuCCON] 995.35 995.34 0.01
L 4.37+4.83 [L+AuCCON] 1307.62 1307.60 0.02
5.1 [L-NH4+AuC
CON] 1289.60 1289.57 0.03
LE 6.62 [LE+AuCCON] 932.29 932.31 0.02
24h
ZF 3.64 [Apo-ZF+CCON] 3143.76 3143.55 0.21
3.89 [Apo-ZF+2CCON] 3324.83 3324.60 0.23
C 5.2 [C+AuCCON] 995.34 995.34 0.0
L 4.27-4.64 [L+AuCCON] 1307.62 1307.60 0.02
4.74-4.93 [L-NH4+AuC
CON] 1289.60 1289.57 0.03
LE 6.5 [LE+AuCCON] 932.29 932.31 0.02
GSH 9.65 [GSH+CCON] 488.15 488.14 0.01
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as for GSH (Figures 3C, S30 and S31). Furthermore, as observed
in the case of complex 4, if the coordination sphere of the AuIII
centre leaves only one position suitable for peptide binding
upon ligand substitution, intermediate I cannot be formed and
the reductive elimination process does not take place. It should
be noted that Gln residues may be alternative binding partners
for gold, facilitating formation of I, as supported by DFT studies.
In conclusion, we have shown here that metal-templated
cross-coupling reactions with peptides cannot be simply
predicted on the basis of the HSAB theory and affinity of the
metal for a certain nucleophile, but require a deeper under-
standing of the mechanisms of reaction and knowledge of the
influence of the chemical and structural complexity of the
target biomolecule on the overall reactivity. Such knowledge,
together with the judicious choice of the ligands stabilizing the
organometallic AuIII centre while enabling its bio-reactivity, will
certainly make gold-promoted reactions a significant addition
to the toolbox of life compatible transformations. In the future,
we envisage the application of AuIII C^N complexes in
proteomic profiling of cysteine residues and of their oxidation
states,[18] as well as catalysts in different cross-coupling proc-
esses in aqueous environment.[19]
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